VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 87 filers reported holding VAXCYTE INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,403,651 | -0.5% | 380,613 | -2.5% | 0.23% | -1.7% |
| Q2 2023 | $19,499,373 | +108.1% | 390,456 | +56.2% | 0.23% | +81.9% |
| Q1 2023 | $9,370,000 | -21.8% | 250,000 | 0.0% | 0.13% | -20.6% |
| Q4 2022 | $11,987,500 | +154.3% | 250,000 | +27.3% | 0.16% | +142.4% |
| Q3 2022 | $4,714,000 | -53.5% | 196,429 | -57.9% | 0.07% | -57.7% |
| Q2 2022 | $10,147,000 | +337.9% | 466,324 | +378.8% | 0.16% | +372.7% |
| Q4 2021 | $2,317,000 | +218.3% | 97,396 | +323.0% | 0.03% | +13.8% |
| Q2 2020 | $728,000 | – | 23,026 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $100,049,000 | 34.21% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $45,299,000 | 18.86% |
| Pivotal bioVenture Partners Investment Advisor LLC | 776,039 | $18,625,000 | 6.81% |
| Kynam Capital Management, LP | 698,638 | $16,767,000 | 3.53% |
| GREAT POINT PARTNERS LLC | 600,000 | $14,400,000 | 3.47% |
| Frazier Life Sciences Management, L.P. | 1,547,405 | $37,138,000 | 2.86% |
| Ghost Tree Capital, LLC | 360,000 | $8,640,000 | 2.42% |
| RA Capital Management | 4,581,203 | $109,949,000 | 2.35% |
| Opaleye Management Inc. | 190,000 | $4,560,000 | 1.88% |
| TPG GP A, LLC | 3,285,504 | $78,852,000 | 1.29% |